 NEW YORK and RESEARCH TRIANGLE PARK, N.C., Nov. 19, 2020 GLOBE NEWSWIRE -- Sio Gene Therapies, Inc. NASDAQ: SIOX, a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announced the appointment of Guangping Gao, Ph.D., as Chief AAV Scientific Advisor. Dr. Gao, a world-recognized scientist and past President of the ASGCT, has played key roles in the discovery and characterization of adeno-associated virus AAV serotypes which were instrumental in the resurgence of gene therapy. In his advisory role, Dr. Gao will provide strategic guidance and scientific and technical input across Sios AAV-based gene therapy programs. 